JP7243021B2 - 免疫チェックポイント阻害薬と併用するプリナブリンの使用 - Google Patents

免疫チェックポイント阻害薬と併用するプリナブリンの使用 Download PDF

Info

Publication number
JP7243021B2
JP7243021B2 JP2017560890A JP2017560890A JP7243021B2 JP 7243021 B2 JP7243021 B2 JP 7243021B2 JP 2017560890 A JP2017560890 A JP 2017560890A JP 2017560890 A JP2017560890 A JP 2017560890A JP 7243021 B2 JP7243021 B2 JP 7243021B2
Authority
JP
Japan
Prior art keywords
cancer
immune checkpoint
composition
checkpoint inhibitor
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017560890A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018508572A5 (enExample
JP2018508572A (ja
Inventor
ファン，ラン
ツァイ－イー リー，グロリア
Original Assignee
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド filed Critical ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド
Publication of JP2018508572A publication Critical patent/JP2018508572A/ja
Publication of JP2018508572A5 publication Critical patent/JP2018508572A5/ja
Priority to JP2022175377A priority Critical patent/JP7564172B2/ja
Application granted granted Critical
Publication of JP7243021B2 publication Critical patent/JP7243021B2/ja
Priority to JP2024167302A priority patent/JP2024174070A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017560890A 2015-02-12 2016-02-11 免疫チェックポイント阻害薬と併用するプリナブリンの使用 Active JP7243021B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022175377A JP7564172B2 (ja) 2015-02-12 2022-11-01 免疫チェックポイント阻害薬と併用するプリナブリンの使用
JP2024167302A JP2024174070A (ja) 2015-02-12 2024-09-26 免疫チェックポイント阻害薬と併用するプリナブリンの使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562115468P 2015-02-12 2015-02-12
US62/115,468 2015-02-12
US201562255259P 2015-11-13 2015-11-13
US62/255,259 2015-11-13
PCT/US2016/017602 WO2016130839A1 (en) 2015-02-12 2016-02-11 Use of plinabulin in combination with immune checkpoint inhibitors

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2021001505A Division JP7157181B2 (ja) 2015-02-12 2021-01-07 免疫チェックポイント阻害薬と併用するプリナブリンの使用
JP2022175377A Division JP7564172B2 (ja) 2015-02-12 2022-11-01 免疫チェックポイント阻害薬と併用するプリナブリンの使用

Publications (3)

Publication Number Publication Date
JP2018508572A JP2018508572A (ja) 2018-03-29
JP2018508572A5 JP2018508572A5 (enExample) 2019-03-22
JP7243021B2 true JP7243021B2 (ja) 2023-03-22

Family

ID=56615698

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017560890A Active JP7243021B2 (ja) 2015-02-12 2016-02-11 免疫チェックポイント阻害薬と併用するプリナブリンの使用
JP2021001505A Active JP7157181B2 (ja) 2015-02-12 2021-01-07 免疫チェックポイント阻害薬と併用するプリナブリンの使用
JP2022175377A Active JP7564172B2 (ja) 2015-02-12 2022-11-01 免疫チェックポイント阻害薬と併用するプリナブリンの使用
JP2024167302A Pending JP2024174070A (ja) 2015-02-12 2024-09-26 免疫チェックポイント阻害薬と併用するプリナブリンの使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021001505A Active JP7157181B2 (ja) 2015-02-12 2021-01-07 免疫チェックポイント阻害薬と併用するプリナブリンの使用
JP2022175377A Active JP7564172B2 (ja) 2015-02-12 2022-11-01 免疫チェックポイント阻害薬と併用するプリナブリンの使用
JP2024167302A Pending JP2024174070A (ja) 2015-02-12 2024-09-26 免疫チェックポイント阻害薬と併用するプリナブリンの使用

Country Status (16)

Country Link
US (1) US20180028531A1 (enExample)
EP (1) EP3256130A4 (enExample)
JP (4) JP7243021B2 (enExample)
KR (2) KR20240110996A (enExample)
CN (2) CN107427510A (enExample)
AU (3) AU2016219204B2 (enExample)
CA (1) CA2975729A1 (enExample)
CL (1) CL2017002050A1 (enExample)
HK (1) HK1247816A1 (enExample)
IL (2) IL286282B2 (enExample)
MX (2) MX394865B (enExample)
MY (1) MY193968A (enExample)
NZ (1) NZ734256A (enExample)
RU (1) RU2723021C2 (enExample)
SG (1) SG11201706281YA (enExample)
WO (1) WO2016130839A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20161157T1 (hr) 2009-03-30 2016-11-18 Eisai R&D Management Co., Ltd. Liposomski pripravak
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
AU2016229295B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
SG10202008673WA (en) 2015-03-06 2020-10-29 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
CN107921018A (zh) * 2015-06-11 2018-04-17 生态有限公司 药物组合及其应用
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
JP2019511565A (ja) 2016-02-08 2019-04-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド ツカレゾールまたはそのアナログを含む組成物
WO2017188350A1 (ja) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
AU2017278245B2 (en) 2016-06-06 2022-09-15 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
JP7198666B2 (ja) 2016-08-26 2023-01-04 哲治 奥野 微小血管血流低減剤およびその利用
EP3525818A1 (en) * 2016-10-14 2019-08-21 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20240110997A (ko) 2017-02-01 2024-07-16 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
NZ778329A (en) * 2017-03-13 2026-03-27 Beyondspring Pharmaceuticals Inc Compositions of plinabulin and use thereof
US11045452B2 (en) 2017-07-26 2021-06-29 Chong Kun Dang Pharmaceutical Corp. Composition for preventing or treating cancer comprising a vascular disrupting agent and immune checkpoint inhibitor
CN111225670A (zh) 2017-09-08 2020-06-02 大学健康网络 抑制Polo样激酶4的组合疗法
CN109498627B (zh) * 2017-09-15 2021-06-04 深圳华大海洋科技有限公司 一种治疗肿瘤的药物组合物及其应用
EP3743074A4 (en) * 2018-01-24 2021-12-15 Beyondspring Pharmaceuticals Inc. COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE
JP7500438B2 (ja) * 2018-06-01 2024-06-17 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Ｅｇｆｒ変異に関連する癌の治療組成物及び治療方法
CN108524442B (zh) * 2018-06-05 2022-01-28 深圳海王医药科技研究院有限公司 一种抗肿瘤药物的注射剂及其制备方法
EP3836930A4 (en) * 2018-08-16 2022-05-11 Beyondspring Pharmaceuticals Inc. Method and composition for stimulating immune response
WO2020092887A2 (en) * 2018-11-01 2020-05-07 North Carolina State University Adipocyte mediated delivery of anticancer therapeutics
CN110265095A (zh) * 2019-05-22 2019-09-20 首都医科大学附属北京佑安医院 用于hcc复发及rfs的预测模型和诺模图的构建方法及应用
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CN112778155B (zh) * 2019-11-11 2023-08-11 大连万春布林医药有限公司 妥卡雷琐衍生物及其用途
MX2022013808A (es) * 2020-05-04 2023-02-09 Beyondspring Pharmaceuticals Inc Terapia de combinacion triple para mejorar la eliminacion de celulas cancerigenas en canceres con baja inmunogenicidad.
WO2022133492A1 (en) * 2020-12-18 2022-06-23 Beyondspring Pharmaceuticals, Inc. Compositions and methods for generating anti-tumor immune response
WO2022216908A1 (en) * 2021-04-09 2022-10-13 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
CN117860672A (zh) 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法
CN121127241A (zh) * 2023-03-10 2025-12-12 万春药业公司 肿瘤联合治疗及使用方法
WO2025006507A1 (en) * 2023-06-27 2025-01-02 Beyondspring Pharmaceuticals, Inc. Oncology combination therapy and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511534A (ja) 2002-08-02 2006-04-06 ネレアス ファーマシューティカルズ インコーポレイテッド デヒドロフェニラヒスチンおよびそれらの類似体、ならびにデヒドロフェニラヒスチンおよびそれらの類似体の合成
JP2013504630A (ja) 2009-09-15 2013-02-07 セルリアン・ファーマ・インコーポレイテッド 癌の治療法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077940A1 (en) * 2004-02-04 2005-08-25 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
PL2161336T5 (pl) * 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
US8569262B2 (en) * 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
KR20100100949A (ko) * 2008-01-08 2010-09-15 브리스톨-마이어스 스큅 컴퍼니 증식성 질환의 치료를 위한 튜불린 조정제와 항-ｃｔｌａ４ 항체의 조합물
US8791102B2 (en) * 2008-10-17 2014-07-29 Exelixis, Inc. Acetanilide sphingosine-1-phosphate receptor antagonists
US20130064831A1 (en) * 2010-05-17 2013-03-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
WO2012035436A1 (en) * 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
US20150004175A1 (en) * 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
FI3381942T4 (fi) * 2012-08-30 2025-12-16 Amgen Inc Menetelmä melanooman hoitamiseksi herpes simplex -virusta ja immuuniaktivaation vapauttajaa käyttäen
US10034939B2 (en) * 2012-10-26 2018-07-31 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
LT2958943T (lt) * 2013-02-20 2020-01-27 The Trustees Of The University Of Pennsylvania Vėžio gydymas, naudojant humanizuotą anti-egfrviii chimerinio antigeno receptorių
WO2014128245A1 (en) * 2013-02-21 2014-08-28 CORAL, Sandra Dna hypomethylating agents for cancer therapy
EP2994530A4 (en) * 2013-05-10 2016-11-16 Whitehead Biomedical Inst PROTEIN MODIFYING LIVING CELLS USING SORTASE
CN105658206A (zh) * 2013-06-03 2016-06-08 诺华股份有限公司 抗pd-l1抗体与mek抑制剂和/或braf抑制剂的组合
EP3076972B1 (en) * 2013-10-11 2021-10-06 BeyondSpring, Inc. Cancer treatment with combination of plinabulin and taxane
JP2019511565A (ja) * 2016-02-08 2019-04-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド ツカレゾールまたはそのアナログを含む組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511534A (ja) 2002-08-02 2006-04-06 ネレアス ファーマシューティカルズ インコーポレイテッド デヒドロフェニラヒスチンおよびそれらの類似体、ならびにデヒドロフェニラヒスチンおよびそれらの類似体の合成
JP2013504630A (ja) 2009-09-15 2013-02-07 セルリアン・ファーマ・インコーポレイテッド 癌の治療法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Ａｎｔｉ－Ｃａｎｃｅｒ Ｄｒｕｇｓ，２００６，１７（１），２５－３１
Ａｒｔｅｒｉｏｓｃｌｅｒ Ｔｈｒｏｍｂ Ｖａｓｃ Ｂｉｏｌ．，２００９，２９，７８９－７９１
Ｂｌｏｏｄ，２０１１，１１７（２１），５６９２－５７００
Ｉｍｍｕｎｉｔｙ，２０１８，４９（６），１１４８－１１６１
Ｉｎｔ．Ｊ．Ｅｘｐ．Ｐａｔｈ．，２００９，９０，２８４－２９４
Ｊｏｕｒｎａｌ ｏｆ Ｌｅｕｋｏｃｙｔｅ Ｂｉｏｌｏｇｙ，２０１３，９４（１），４１－５３
Ｎａｔ Ｒｅｖ Ｃａｎｃｅｒ．，２０１２，１２（４），２５２－２６４

Also Published As

Publication number Publication date
NZ750444A (en) 2021-03-26
AU2016219204A1 (en) 2017-08-24
NZ734256A (en) 2019-02-22
US20180028531A1 (en) 2018-02-01
RU2017127966A3 (enExample) 2019-06-20
KR20240110996A (ko) 2024-07-16
AU2021202416B2 (en) 2024-02-15
CN107427510A (zh) 2017-12-01
CN117100753A (zh) 2023-11-24
AU2024200672A1 (en) 2024-02-22
IL253784B (en) 2021-09-30
RU2723021C2 (ru) 2020-06-08
IL253784A0 (en) 2017-09-28
CL2017002050A1 (es) 2018-04-13
AU2024200672B2 (en) 2026-03-05
JP7564172B2 (ja) 2024-10-08
IL286282B1 (en) 2023-06-01
JP2024174070A (ja) 2024-12-13
IL286282B2 (en) 2023-10-01
HK1247816A1 (zh) 2018-10-05
BR112017016902A2 (pt) 2018-03-27
MX2017010338A (es) 2017-12-20
MX2022007472A (es) 2022-06-29
KR20170117113A (ko) 2017-10-20
EP3256130A4 (en) 2018-08-01
JP7157181B2 (ja) 2022-10-19
RU2017127966A (ru) 2019-03-12
SG11201706281YA (en) 2017-09-28
IL286282A (en) 2021-10-31
MY193968A (en) 2022-11-03
WO2016130839A1 (en) 2016-08-18
JP2018508572A (ja) 2018-03-29
MX394865B (es) 2025-03-24
CA2975729A1 (en) 2016-08-18
JP2022190005A (ja) 2022-12-22
AU2016219204B2 (en) 2021-01-21
AU2021202416A1 (en) 2021-05-20
EP3256130A1 (en) 2017-12-20
JP2021050247A (ja) 2021-04-01

Similar Documents

Publication Publication Date Title
JP7157181B2 (ja) 免疫チェックポイント阻害薬と併用するプリナブリンの使用
US11857522B2 (en) Compositions containing tucaresol or its analogs
JP2023524530A (ja) 免疫原性が低い癌の癌細胞死滅を増強するための３剤併用療法
US20250073230A1 (en) Use of plinabulin in combination with immune checkpoint inhibitors
JP2024513505A (ja) 腫瘍を治療するための組成物及び方法
HK40099485A (zh) 普那布林联合免疫检查点抑制剂的用途
NZ750444B2 (en) Use of plinabulin in combination with immune checkpoint inhibitors
TW202315631A (zh) 增強低免疫原性癌症中癌細胞毒殺的三聯療法
BR112017016902B1 (pt) Composição farmacêutica, respectivo uso e uso de plinabulina
HK40102238A (zh) 用於治疗肿瘤的治疗组合物和方法
CN117615761A (zh) 用于治疗肿瘤的治疗组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190208

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200420

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210107

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210107

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210120

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210126

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210326

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210330

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220105

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220510

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221101

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20230110

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20230207

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20230207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230220

R150 Certificate of patent or registration of utility model

Ref document number: 7243021

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250